

MAP Health Equity Advisory Group 2021-2022 Pre-Rulemaking Review Meeting

December 9, 2021 10:00 am – 6:00 pm ET

Participant Instructions

Follow the instructions below 15 minutes prior to the scheduled start time.

- 1. Please click on the meeting link: https://nqf.webex.com/nqf/j.php?MTID=m45da12198b514ec635dbc9350cc36013
- 2. Meeting number: 179 404 3330 / Password: yqFjPMvZ624
- 3. To join by phone, please call 415-655-0001 and enter the access code: 179 404 3330
- 4. To unmute/mute your phone line, use *6.

Meeting Objectives

- Review and provide input on Measures Under Consideration (MUC) for the MAP Hospital, MAP Post-Acute Care/Long-Term Care (PAC/LTC), and MAP Clinician programs with a health equity lens
- Identify measure gaps for the MAP Hospital, MAP PAC/LTC, and MAP Clinician programs

10:00 am	Welcome, Introductions, Disclosures of Interest, and Review of Meeting Objectives Rebekah Angove, Advisory Group Co-Chair
	Laurie Zephyrin, Advisory Group Co-Chair
	Kathleen Giblin, Senior Vice President, Emerging Initiatives, National Quality Forum (NQF)
	Chelsea Lynch, Director, Emerging Initiatives, NQF
	Victoria Freire, Analyst, Emerging Initiatives, NQF
10:20 am	CMS Opening Remarks Michelle Schreiber, Deputy Director for Quality and Value, Centers for Medicare & Medicaid Services (CMS)
10:50am	Overview of Pre-Rulemaking Approach
	Amy Guo, Manager, Emerging Initiatives, NQF
11:00 am	Discuss Measures Under Consideration
	• Merit-Based Incentive Payment System (MIPS) Program Measures
	• MUC2021-125: Psoriasis – Improvement in Patient-Reported Itch Severity
	 MUC2021-135: Dermatitis – Improvement in Patient-Reported Itch Severity
	• MUC2021-063: Care Goal Achievement Following a Total Hip Arthroplasty
	(THA) or Total Knee Arthroplasty (TKA)



	 MUC2021-107: Clinician-Level and Clinician Group-Level Total Hip Arthroplasty and/or Total Knee Arthroplasty (THA and TKA) Patient- Reported Outcome-Based Performance Measure (PRO-PM) MUC2021-090: Kidney Health Evaluation MUC2021-127: Adult Kidney Disease: Angiotensin Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy MUC2021-105: Mismatch Repair (MMR) or Microsatellite Instability (MSI) Biomarker Testing Status in Colorectal Carcinoma, Endometrial, Gastroesophageal, or Small Bowel Carcinoma MUC2021-058: Appropriate intervention of immune-related diarrhea and/or colitis in patients treated with immune checkpoint inhibitors
12:30 pm	Lunch
1:00 pm	 Discuss Measures Under Consideration Skilled Nursing Facility Quality Reporting Program (SNF QRP)
	 Skilled Nursing Facility Quality Reporting Program (SNF QRP) MUC2021-123: Influenza Vaccination Coverage Among Healthcare Personnel
	 Skilled Nursing Facility Value-Based Purchasing (SNF VBP) Program MUC2021-095: CoreQ: Short Stay Discharge Measure MUC2021-130: Discharge to Community-Post Acute Care Measure for Skilled Nursing Facilities (SNF) MUC2021-124: Skilled Nursing Facility Healthcare-Associated Infections Requiring Hospitalization MUC2021-137: Total Nursing Hours Per Resident Day MUC2021-136: Screening for Social Drivers of Health Merit-based Incentive Payment System Hospital Inpatient Quality Reporting Program MUC2021-084: Hospital Harm – Opioid-Related Adverse Events Hospital Inpatient Quality Reporting Program
	 Medicare Promoting Interoperability Program for Hospitals
2:30 pm	Break
2:40 pm	 Discuss Measures Under Consideration Medicare Parts C & D Star Ratings MUC2021-053: Concurrent Use of Opioids and Benzodiazepines (COB) MUC2021-056: Polypharmacy: Use of Multiple Anticholinergic Medications in Older Adults (Poly-ACH) MUC2021-066: Polypharmacy: Use of Multiple Central Nervous System (CNS)-Active Medications in Older Adults (Poly-CNS) End-Stage Renal Disease Quality Incentive Program (ESRD QIP) MUC2021-101: Standardized Readmission Ratio (SRR) for Dialysis Facilities Hospital Inpatient Quality Reporting Program (Hospital IQR Program) MUC2021-106: Hospital Commitment to Health Equity

PAGE 3

- MUC2021-122: Excess Days in Acute Care (EDAC) After Hospitalization For Acute Myocardial Infarction (AMI)
- MUC2021-120: Hospital-Level, Risk-Standardized Payment Associated With an Episode of Care for Primary Elective Total Hip and/or Total Knee Arthroplasty (THA/TKA)
- PPS-Exempt Cancer Hospital Quality Reporting (PCHQR)
 - MUC2021-091: Appropriate Treatment for Patients With Stage I (T1c) Through III HER2 Positive Breast Cancer
- 4:10 pm Break

4:20 pm Discuss Measures Under Consideration

- MUC2021-118: Hospital-Level Risk-Standardized Complication Rate (RSCR) Following Elective Primary Total Hip Arthroplasty (THA) and/or Total Knee Arthroplasty (TKA)
 - Hospital Inpatient Quality Reporting Program
 - Hospital Value-Based Purchasing Program
- MUC2021-131: Medicare Spending Per Beneficiary (MSPB) Hospital
 - Hospital Inpatient Quality Reporting Program
 - Hospital Value-Based Purchasing Program
- MUC2021-104: Severe Obstetric Complications eCQM
 - Hospital Inpatient Quality Reporting Program
 - Medicare Promoting Interoperability Program for Hospitals
- MUC2021-098: National Healthcare Safety Network (NHSN) Healthcareassociated Clostridioides difficile Infection Outcome Measure
 - Hospital-Acquired Condition Reduction Program
 - Hospital Inpatient Quality Reporting Program
 - Medicare Promoting Interoperability Program for Hospitals
 - Prospective Payment System (PPS)-Exempt Cancer Hospitals Quality Reporting Program
 - Inpatient Rehabilitation Facility Quality Reporting Program
 - Long-Term Care Hospital Quality Reporting Program
 - Skilled Nursing Facility Quality Reporting Program
- MUC2021-100: National Healthcare Safety Network (NHSN) Hospital-Onset Bacteremia & Fungemia Outcome Measure
 - Hospital-Acquired Condition Reduction Program
 - Hospital Inpatient Quality Reporting Program
 - Medicare Promoting Interoperability Program for Hospitals
 - Prospective Payment System (PPS)-Exempt Cancer Hospitals Quality Reporting Program
- 5:00 pm Discussion of MAP Health Equity Advisory Group Review Process
- 5:45 pm Opportunity for Public Comment
- 5:55 pm Next Steps and Closing Comments Rebekah Angove, Laurie Zephyrin, and Victoria Freire
- 6:00 pm Adjourn